These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 17157859)
1. Lipoprotein-associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids. Schmidt EB; Koenig W; Khuseyinova N; Christensen JH Atherosclerosis; 2008 Jan; 196(1):420-424. PubMed ID: 17157859 [TBL] [Abstract][Full Text] [Related]
2. Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease. Xu RX; Zhang Y; Li XL; Li S; Guo YL; Dong Q; Liu G; Li JJ Clin Chim Acta; 2015 Jun; 446():195-200. PubMed ID: 25934512 [TBL] [Abstract][Full Text] [Related]
3. The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Pedersen MW; Koenig W; Christensen JH; Schmidt EB Eur J Nutr; 2009 Feb; 48(1):1-5. PubMed ID: 19030909 [TBL] [Abstract][Full Text] [Related]
4. Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up. Rallidis LS; Tellis CC; Lekakis J; Rizos I; Varounis C; Charalampopoulos A; Zolindaki M; Dagres N; Anastasiou-Nana M; Tselepis AD J Am Coll Cardiol; 2012 Nov; 60(20):2053-60. PubMed ID: 23083783 [TBL] [Abstract][Full Text] [Related]
5. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A; J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114 [TBL] [Abstract][Full Text] [Related]
6. Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A(2) in patients with stable angina. Gajos G; Zalewski J; Mostowik M; Konduracka E; Nessler J; Undas A Nutr Metab Cardiovasc Dis; 2014 Apr; 24(4):434-9. PubMed ID: 24555913 [TBL] [Abstract][Full Text] [Related]
7. Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Hatoum IJ; Nelson JJ; Cook NR; Hu FB; Rimm EB Am J Clin Nutr; 2010 Mar; 91(3):786-93. PubMed ID: 20107195 [TBL] [Abstract][Full Text] [Related]
8. Elevated plasma lipoprotein-associated phospholipase A₂ activity is associated with plaque rupture in patients with coronary artery disease. Liu CF; Qin L; Ren JY; Chen H; Wang WM; Liu J; Song JX; Li LJ Chin Med J (Engl); 2011 Aug; 124(16):2469-73. PubMed ID: 21933589 [TBL] [Abstract][Full Text] [Related]
9. Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study. Kim JY; Hyun YJ; Jang Y; Lee BK; Chae JS; Kim SE; Yeo HY; Jeong TS; Jeon DW; Lee JH Am J Clin Nutr; 2008 Sep; 88(3):630-7. PubMed ID: 18779277 [TBL] [Abstract][Full Text] [Related]
10. Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians. Anuurad E; Ozturk Z; Enkhmaa B; Pearson TA; Berglund L J Clin Endocrinol Metab; 2010 May; 95(5):2376-83. PubMed ID: 20194707 [TBL] [Abstract][Full Text] [Related]
11. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9. Constantinides A; Kappelle PJ; Lambert G; Dullaart RP Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679 [TBL] [Abstract][Full Text] [Related]
12. Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population. Cai A; Li G; Chen J; Li X; Li L; Zhou Y BMC Cardiovasc Disord; 2015 Feb; 15():14. PubMed ID: 25879827 [TBL] [Abstract][Full Text] [Related]
14. Association of lipoprotein-associated phospholipase A₂ with characteristics of vulnerable coronary atherosclerotic plaques. Liu YS; Hu XB; Li HZ; Jiang WD; Wang X; Lin H; Qin AQ; Wang YM; Zhao T; Dong ZQ; Zhang M; Lu QH Yonsei Med J; 2011 Nov; 52(6):914-22. PubMed ID: 22028154 [TBL] [Abstract][Full Text] [Related]
15. Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy. Reddy KJ; Singh M; Batsell RR; Bangit JR; Miraskar RA; Zaheer MS Prev Cardiol; 2010; 13(3):130-4. PubMed ID: 20626668 [TBL] [Abstract][Full Text] [Related]